NEXTBio Capital Management LP Takes Position in Shattuck Labs, Inc. $STTK

NEXTBio Capital Management LP acquired a new stake in shares of Shattuck Labs, Inc. (NASDAQ:STTK) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,149,907 shares of the company’s stock, valued at approximately $11,497,000. Shattuck Labs makes up approximately 6.7% of NEXTBio Capital Management LP’s portfolio, making the stock its 5th biggest holding. NEXTBio Capital Management LP owned about 4.98% of Shattuck Labs as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of STTK. Virtu Financial LLC acquired a new position in shares of Shattuck Labs during the third quarter valued at about $38,000. AQR Capital Management LLC increased its holdings in shares of Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after acquiring an additional 31,355 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Shattuck Labs during the second quarter valued at about $44,000. Squarepoint Ops LLC acquired a new position in shares of Shattuck Labs during the third quarter valued at about $46,000. Finally, Bridgeway Capital Management LLC increased its holdings in shares of Shattuck Labs by 147.5% during the second quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock valued at $73,000 after acquiring an additional 55,000 shares in the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on STTK shares. Wedbush upped their target price on Shattuck Labs from $8.00 to $11.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Wall Street Zen upgraded Shattuck Labs from a “hold” rating to a “buy” rating in a research report on Saturday. Needham & Company LLC upped their target price on Shattuck Labs from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, June 8th. TD Cowen reiterated a “buy” rating on shares of Shattuck Labs in a research report on Friday, March 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Shattuck Labs in a research report on Monday, June 8th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Insiders Place Their Bets

In other Shattuck Labs news, Director Clay B. Siegall purchased 62,500 shares of the stock in a transaction dated Tuesday, June 9th. The stock was acquired at an average cost of $4.00 per share, for a total transaction of $250,000.00. Following the acquisition, the director owned 318,608 shares in the company, valued at $1,274,432. This trade represents a 24.40% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Arundathy N. Pandite sold 30,000 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $6.61, for a total value of $198,300.00. Following the transaction, the insider owned 166,219 shares of the company’s stock, valued at approximately $1,098,707.59. This represents a 15.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 8.79% of the stock is owned by company insiders.

Shattuck Labs Price Performance

Shares of STTK stock opened at $4.94 on Friday. The company has a market cap of $378.80 million, a price-to-earnings ratio of -7.84 and a beta of 1.08. The stock has a 50 day simple moving average of $6.35 and a 200-day simple moving average of $4.94. Shattuck Labs, Inc. has a 1-year low of $0.71 and a 1-year high of $8.33.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, May 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. During the same period last year, the company earned ($0.27) EPS. Analysts anticipate that Shattuck Labs, Inc. will post -0.51 earnings per share for the current fiscal year.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.